Michael Bokoch

Has grant

Associate Professor

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Endothelial Activation by Liver Reperfusion Injury in Transplantation

Open Date: 2020-07-01

Close Date: 2022-06-30

Articles (21)

Year:

2026

Year:

2026

General anesthetics are essential for invasive medical procedures; however, there remains a need for safer agents. Using a bespoke 96-well-plate format platform enabling high-throughput imaging of larval zebrafish behavior, we screened 12,000 compounds and identified an isoxazole chemotype that phenocopies the intravenous anesthetics etomidate and propofol. Its optimization via medicinal chemistry yielded a novel anesthetic that we call nidradine. This anesthetic is efficacious in both zebrafish and mice and lacks the problematic adrenal suppression characteristic of etomidate. Mechanistic studies via electrophysiology and structural biology revealed that nidradine, like etomidate and propofol, is a positive allosteric modulator of the GABA A receptor. Remarkably, behavioral assays in mice demonstrate that nidradine differs from most general anesthetics in that it also produces analgesia.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Background. Early extubation after liver transplantation can decrease cost and intensive care unit lengths of stay, but its adoption remains limited because of safety concerns. We assessed the feasibility and safety of early extubation at a liver transplant center with a high early extubation rate. We analyzed subgroups of high-risk patients, including high model for end-stage liver disease-sodium (MELD-Na) score, high intraoperative blood loss, and patients undergoing simultaneous liver-kidney transplantation. Methods. We included all adult liver transplantations performed at a single center between June 2012 and July 2022. Patients were divided into 2 groups: (1) those extubated early (ie, in the operating room or within the first hour of intensive care unit admission) and (2) those who underwent delayed extubation. The primary outcome was reintubation within 48 h after early extubation. Rates of early extubation were analyzed separately for quartiles of MELD-Na score and intraoperative blood loss. Results. Of 1555 patients, 969 (62%) were extubated early. Of these, 31 patients (3.2%) required mechanical ventilation within 48 h postoperatively: 11 patients (1.1%) were reintubated for respiratory failure and 20 (2.1%) remained intubated after reoperation. There was no difference in postoperative pneumonia between the groups ( P = 0.059). Early extubation rates inversely correlated with the quartiles of MELD-Na score and estimated blood loss. In the highest quartile for MELD-Na (>34) and estimated blood loss (>5 L), 34% of patients were extubated early. Conclusions. Early extubation of properly selected patients after liver transplantation is safe and associated with a low rate of reintubation, even among select groups of high-risk patients.

Year:

2025

Acute kidney injury is a common complication after liver transplantation. Acute kidney injury occurrence in this population determines higher mortality, increased graft loss, longer hospital and intensive care unit stays, and more progression to chronic kidney disease. Hemodynamic derangements are treated intraoperatively with vasopressor medications to uphold a mean arterial pressure within the autoregulatory range of the kidney, but the impact of their use, as well as the choice of medication, on postoperative kidney function, is relatively unknown. Vasopressin acts as a portal flow modulator, has a potential catecholamine-sparing effect, and provides benefits for kidney function during distributive shock. The investigators hypothesized that the intraoperative use of vasopressin could reduce the incidence of postoperative severe acute kidney injury after liver transplantation and planned a retrospective single-center propensity score-adjusted regression analysis to test this hypothesis.

Year:

2024

Sera from patients in our UCSF Liver Transplant Biobank are used to stimulate human pulmonary microvascular endothelial cells (HPMECs) grown to confluency on ECIS platform. This protocol prospectively defines the plan for data analysis from these experiments.

Year:

2024

Sera from patients in our UCSF Liver Transplant Biobank are used to stimulate human pulmonary microvascular endothelial cells (HPMECs) grown to confluency on ECIS platform. This protocol prospectively defines the plan for data analysis from these experiments.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (12)

Brian K. Shoichet

University of California, San Francisco

UNITED STATES
View details

Hillary Braun

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Matthieu Legrand

Prof

UCSF Medical Center

UNITED STATES
View details

Matthew McCarroll

Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Elizabeth Whitlock

Associate Professor

UCSF Medical Center

UNITED STATES
View details

Allan Basbaum

University of California

UNITED STATES
View details

Ryan Hibbs

Professor

University of California, San Diego

UNITED STATES
View details

Oliver Kimberger

Deputy Head of Department (Geschäftsführender Oberarzt)

Medical University of Vienna

AUSTRIA
View details

Dieter Adelmann

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Garrett Roll

Associate Professor of Surgery

University of California, San Francisco

UNITED STATES
View details

Kerstin Kolodzie

University of California, San Francisco

UNITED STATES
View details

Michael Mathis

Associate Professor

University of Michigan

UNITED STATES
View details